Home » Stocks » AKBA

Akebia Therapeutics, Inc. (AKBA)

Stock Price: $2.47 USD -0.05 (-1.98%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $2.50 +0.03 (1.22%) Jul 30, 7:43 PM
Market Cap 396.28M
Revenue (ttm) 259.13M
Net Income (ttm) -392.29M
Shares Out 153.82M
EPS (ttm) -2.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $2.47
Previous Close $2.52
Change ($) -0.05
Change (%) -1.98%
Day's Open 2.54
Day's Range 2.45 - 2.58
Day's Volume 2,028,120
52-Week Range 2.09 - 11.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LOS ANGELES--(BUSINESS WIRE)---- $AKBA #AKBA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc.

3 days ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $akba #LawFirm--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders...

4 days ago - Business Wire

CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

4 days ago - PRNewsWire

Reddit penny stocks are in focus right now; here's 3 to watch The post These Penny Stocks Are Frequently Talked About on Reddit, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other stocks mentioned: EBON, ENZC
1 week ago - PennyStocks

Which penny stocks are the best for your watchlist in 2021? The post Best 3 Penny Stocks to Watch Right Now, Worth it or Not?

Other stocks mentioned: BRQS, NMTR
2 weeks ago - PennyStocks

CAMBRIDGE, Mass., July 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 25...

4 weeks ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - June 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Akebia...

1 month ago - Newsfile Corp

Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the development and commercialization of praliciguat. Un...

Other stocks mentioned: CYCN
1 month ago - Benzinga

CAMBRIDGE, Mass., June 3, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., June 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 15...

1 month ago - PRNewsWire

Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat's marketing application for anemia due to chronic k...

1 month ago - Benzinga

CAMBRIDGE, Mass. and TOKYO, June 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney diseas...

1 month ago - PRNewsWire

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

These Reddit penny stocks are climbing today; are they worth adding to your watchlist? The post These Reddit Penny Stocks Are Soaring Today, Are They Worth Buying?

Other stocks mentioned: HTZGQ, ZYNE
2 months ago - PennyStocks

AKBA, CNA, EBMT, FCEL, and HMPT have been added to the Zacks Rank #5 (Strong Sell) List on May 12, 2021

Other stocks mentioned: CNA, EBMT, FCEL, HMPT
2 months ago - Zacks Investment Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -36.36% and 19.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Akebia Therapeutics (NASDAQ:AKBA) fell 1.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 4.26% year over year to ($0.45), which missed...

2 months ago - Benzinga

CAMBRIDGE, Mass., May 10, 2021 /PRNewswire/ -- Akebia Therapeutics ® , Inc.

2 months ago - PRNewsWire

Akebia Therapeutics Inc ( AKBA , Financial), Adverum Biotechnologies Inc ( ADVM , Financial) have performed so poorly over the prior 52 weeks through May 5, with the share prices losing more than 59%, t...

Other stocks mentioned: ADVM
2 months ago - GuruFocus

CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 9 n...

2 months ago - PRNewsWire

CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

3 months ago - PRNewsWire

CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

3 months ago - PRNewsWire

NEW YORK, April 26, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...

3 months ago - PRNewsWire

CAMBRIDGE, Mass., April 12, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

3 months ago - PRNewsWire

Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.

3 months ago - Zacks Investment Research

TOKYO & PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that its collaborator Akebia Therapeutics, Inc. (Akebia) has submitted a New Drug Application (NDA) to the Fo...

4 months ago - Business Wire

CAMBRIDGE, Mass., March 30, 2021 /PRNewswire/ --  Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, tod...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., March 25, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA),  today announced that its collaboration partner, Japan Tobacco Inc. (JT), received approval from the Pharmaceut...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., March 11, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, celebrat...

4 months ago - PRNewsWire

With the trading day about halfway over, the broad markets were pushing higher on the day.

Other stocks mentioned: BMBL, NEE, WPM, ARAV, BGNE, IMO, IOVA ...
4 months ago - 24/7 Wall Street

CAMBRIDGE, Mass., March 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted f...

4 months ago - PRNewsWire

Investors were not impressed with the drugmaker's latest quarterly update.

5 months ago - The Motley Fool

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appo...

5 months ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 19...

5 months ago - PRNewsWire

With the trading day practically over, the broad markets were sliding into the weekend.

Other stocks mentioned: BIIB, DDD, DUK, F, HOG, LXRX, MTN ...
6 months ago - 24/7 Wall Street

CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno...

6 months ago - PRNewsWire

CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted ei...

6 months ago - PRNewsWire

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno...

7 months ago - PRNewsWire

CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 ...

7 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

8 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 16, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

8 months ago - PRNewsWire

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 ...

8 months ago - PRNewsWire

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 23, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that evaluated the ef...

9 months ago - PRNewsWire

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis;... [Read more...]

Industry
Biotechnology
IPO Date
Mar 20, 2014
CEO
John Butler
Employees
379
Stock Exchange
NASDAQ
Ticker Symbol
AKBA
Full Company Profile

Financial Performance

In 2020, AKBA's revenue was $295.31 million, a decrease of -11.85% compared to the previous year's $335.00 million. Losses were -$383.46 million, 37.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for AKBA stock is "Buy." The 12-month stock price forecast is 6.57, which is an increase of 165.99% from the latest price.

Price Target
$6.57
(165.99% upside)
Analyst Consensus: Buy